Conditions: Hereditary Angioedema
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with Icatibant in a medical facility.

Detailed description:

Arms:
arm 1: Open-label study

Interventions: intervention 1: Icatibant
Intervention descriptions: intervention 1: 30 mg subcutaneous dose of Icatibant

Protocol document: